Anticompetitive mergers in the pharmaceutical industry have increasingly drawn scrutiny from regulators, policymakers, and public health advocates as companies pursue buyouts not for innovation, but to eliminate competition and extend market dominance. This strategy — acquiring potential rivals or generic manufacturers to delay lower-cost alternatives — raises significant concerns about drug affordability, patient access, and the integrity of competitive markets. While pharmaceutical innovation remains critical, the growing use of mergers as a tool to suppress competition rather than foster it has prompted calls for stronger antitrust enforcement and greater transparency in corporate dealings.
The practice gained renewed attention following a 2023 analysis in the Latest England Journal of Medicine that documented how large pharmaceutical firms have used acquisitions to neutralize emerging threats to their flagship drugs, particularly in therapeutic areas like oncology, immunology, and rare diseases. Rather than investing in novel research, some companies opt to purchase competitors holding promising pipeline drugs or generic versions, effectively shelving them to protect existing revenue streams. This approach, sometimes referred to as “killer acquisitions,” allows dominant firms to maintain high prices long after patents would normally expire, undermining the intended balance of the patent system between innovation incentive and public access.
One of the most cited examples involves the acquisition of Arrowhead Pharmaceuticals’ RNAi platform interests by larger entities seeking to control emerging gene-silencing technologies. While Arrowhead remains independent, similar patterns have emerged with smaller biotechs developing biosimilars or next-generation therapies. In 2022, the Federal Trade Commission (FTC) challenged Amgen’s $27.8 billion acquisition of Horizon Therapeutics, arguing the deal would reduce competition in drugs for rare inflammatory diseases by allowing Amgen to bundle Horizon’s products with its own blockbuster Enbrel. Although a federal judge ultimately allowed the merger to proceed in 2023, the case highlighted growing regulatory concern over vertical and horizontal consolidation in specialty pharmaceutical markets.
The FTC has since intensified its review of pharmaceutical mergers, particularly those involving potential generic competitors. In 2023, the agency issued a policy statement signaling a more aggressive stance toward vertical mergers that could enable dominant firms to foreclose competition through control of distribution channels, rebate structures, or formulary access. Similarly, the European Commission has blocked or conditioned several high-profile pharma deals over antitrust concerns, including vetoing Illumina’s proposed acquisition of Grail in 2022 over fears it would stifle innovation in early cancer detection — a decision later upheld by the EU’s General Court in 2023.
These actions reflect a broader shift in antitrust philosophy, moving from a narrow focus on immediate price effects to considering long-term impacts on innovation and market entry. Critics argue that when large pharmaceutical companies acquire rivals not to integrate their research but to discontinue it, they distort market dynamics and erode public trust. A 2021 study by researchers at the University of Minnesota found that nearly 60% of acquired pipeline drugs in oncology were discontinued within five years of acquisition, suggesting that innovation suppression — not enhancement — was a motivating factor in many cases.
The human cost of such strategies is measurable. When generic or biosimilar entry is delayed, patients face prolonged exposure to high drug prices. For example, the absence of a biosimilar to Humira (adalimumab) in the United States until 2023 — despite European availability years earlier — resulted in tens of billions of dollars in excess spending by patients, insurers, and government programs. While legal settlements and patent thickets played a role, analyses have shown that strategic acquisitions and litigation tactics by AbbVie delayed biosimilar competition far beyond what patent expiry alone would have allowed.
Transparency remains a major obstacle. Unlike clinical trial data or safety disclosures, merger motivations are rarely disclosed in public filings. Companies typically cite “synergies” or “strategic alignment” as rationales, making it difficult for regulators to distinguish between pro-competitive integration and anti-competitive elimination. Advocacy groups such as the American Economic Liberties Project and Public Citizen have called for mandatory disclosure of post-merger R&D plans and pipeline commitments as a condition of approval for large pharmaceutical acquisitions.
Legislative efforts are underway to address these gaps. In the United States, the Prescription Drug Pricing Reduction Act, reintroduced in Congress in 2023, includes provisions to strengthen FTC authority over pharmaceutical mergers and require greater reporting on post-acquisition drug development. Similarly, the Inflation Reduction Act’s drug negotiation provisions, while primarily focused on Medicare pricing, have indirectly increased scrutiny on how monopolistic practices contribute to unsustainable spending.
Internationally, the World Health Organization has urged member states to consider competition policy as part of essential medicines access strategies. In its 2022 report on local production of medicines, the WHO emphasized that unchecked consolidation in the pharmaceutical sector undermines resilience and equity, particularly in low- and middle-income countries dependent on affordable generics.
As enforcement actions increase and public awareness grows, the pharmaceutical industry faces mounting pressure to justify mergers not just as financially beneficial, but as socially responsible. The coming years will likely see more rigorous scrutiny of acquisition motives, especially when they involve emerging therapies or potential generic entrants. For patients, providers, and payers, the outcome of this debate will shape not only drug prices but the very direction of medical innovation.
The next major development to watch is the FTC’s ongoing review of vertical merger guidelines, with a public comment period expected to close in late 2024 and final policy anticipated in early 2025. Stakeholders are encouraged to monitor the Federal Trade Commission’s website for updates on antitrust enforcement actions and policy changes affecting healthcare markets.
If you found this analysis informative, please consider sharing it with colleagues or leaving a comment below to join the conversation on healthcare competition and patient access.